Article Text

other Versions

PDF
Correspondence
The Authors' reply
  1. Alex Pitcher1,
  2. Deborah Ashby2,
  3. Paul Elliott3,
  4. Steffen E Petersen4
  1. 1Department of Cardiovascular Medicine, Oxford Centre for Clinical Magnetic Resonance Research, University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK
  2. 2Imperial Clinical Trials Unit, School of Public Health, Imperial College London, St Mary's Campus, Norfolk Place, London, UK
  3. 3Department of Epidemiology and Biostatistics, MRC-HPA Centre for Environment and Health, School of Public Health, Imperial College London, St Mary's Campus, Norfolk Place, London, UK
  4. 4Centre for Advanced Cardiovascular Imaging, William Harvey Research Institute, Barts and The London NIHR Biomedical Research Unit, The London Chest Hospital, London, UK
  1. Correspondence to Dr Steffen E Petersen, Centre Lead for Advanced Cardiovascular Imaging, William Harvey Research Institute, Barts and The London NIHR Biomedical Research Unit, The London Chest Hospital, Bonner Road, London, E2 9JX UK; s.e.petersen{at}qmul.ac.uk

Statistics from Altmetric.com

The Authors' reply We are grateful to Dr Eitel and colleagues for their interest1 in our recent review.2 This paper was intended primarily to emphasise the principles of application of this powerful and expanding set of techniques to clinical trials and to provide a few examples of (generally) well-established biomarkers, rather than to provide an exhaustive list of all established and emerging techniques of potential utility. We welcome the attention that they bring to several emerging biomarkers, which show considerable promise as reliable surrogate …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles